Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Illegal internet pharmacists arrested in US
This DEA-led investigative effort is the first to target e-trafficking located solely within the US. The alleged drug dealers who operated these rogue internet pharmacies received prescription orders
This DEA-led investigative effort is the first to target e-trafficking located solely within the US. The alleged drug dealers who operated these rogue internet pharmacies received prescription orders
The company indicated in a statement that it does not believe that it has done anything wrong, but that it decided to settle the case to avoid litigation.
The technology allows for zolmitriptan to be initially administered quickly in order to produce fast-acting pain relief for the migraine sufferer, followed by a slow release of the
Results following 12 weeks of treatment confirmed findings from a previous study in not showing a statistically significant benefit of Phenserine treatment over placebo. Patient recruitment for these
The FDA decision is another major blow for Pfizer. At best parecoxib’s path to approval will now be delayed, but the letter could also indicate that the US
The objectives of the study are to determine the response rate and toxicity of Cloretazine in patients with locally advanced or metastatic small-cell lung cancer who have either
ISIS 301012 is a second-generation antisense drug that targets apoB-100, the protein component of low density lipoprotein (LDL, or “bad”) cholesterol. Lowering cholesterol levels is key to the
Berlex’s Zevalin, recently approved in Canada, is indicated for the treatment of adult patients with a certain type of non-Hodgkin’s lymphoma. Zevalin combines the targeting ability of an
In the phase I trial, approximately 70 healthy volunteers will be randomized to receive orally-administered CRA-028129 or placebo. The dose amount and number of days of dosing will
The drug is currently in phase III clinical trials as a treatment for peritumoral edema, or swelling associated with brain tumors. Neurobiological Technologies (NTI) is also eligible to